期刊
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
卷 51, 期 1, 页码 60-68出版社
SPRINGER HEIDELBERG
DOI: 10.1177/2168479016663265
关键词
adaptive trials; phase II/III seamless trial; sample size reassessment; Type I error; data monitoring committee
The draft adaptive design guidance released by FDA in 2010 included references to adaptive study designs that were described as less well-understood. At that time, there was relatively little regulatory experience with such designs, and their properties were felt to be insufficiently understood. In order to promote greater use of adaptive designs, especially those categorized as less well-understood, the Best Practice Subteam of the DIA Adaptive Designs Scientific Working Group (ADSWG) has worked on describing and characterizing these designs, identifying challenges associated with them and suggesting improvements to design or study conduct aspects that might make them more acceptable. This paper summarizes the work from the subteam.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据